Citations 1
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML
Johnson, Mary Ann , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Foran, James M. , Baer, Maria R. , Kovacsovics, Tibor , Olin, Rebecca L. , Blum, William , Schiller, Gary J. , Redner, Robert L. , Al‐Mansour, Zeina , Curran, Emily , Heerema, Nyla A. , Martycz, Molly , Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O. , Stefanos, Mona , Druggan, Franchesca , Burd, Amy , Borate, Uma , Byrd, John C. , Byrd, John C , Zeidner, Joshua F. , Foster, Matthew C , Johnson, Mary, Stock, Wendy , Madanat, Yazan F. , Lin, Tara L. , Chen, Timothy Frank , Levine, Ross L. , Druker, Brian J , Mims, Alice S
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9070-9073
